"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
    
			
			
				
				
					
						| Descriptor ID | 
										
							D011518
						 | 			
					
					
						| MeSH Number(s) | 
						
							 D12.776.624.664.700 
						 | 
					
					
						| Concept/Terms | 
						
							Proto-Oncogene Proteins- Proto-Oncogene Proteins
 - Proto Oncogene Proteins
 - Proto-Oncogene Products, Cellular
 - Cellular Proto-Oncogene Products
 - Proto Oncogene Products, Cellular
 - Proto Oncogene Proteins, Cellular
 - c-onc Proteins
 - c onc Proteins
 - Cellular Proto-Oncogene Proteins
 - Cellular Proto Oncogene Proteins
 - Proto-Oncogene Proteins, Cellular
 
  
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 1995 | 6 | 1 | 7 | 
| 1996 | 16 | 2 | 18 | 
| 1997 | 10 | 4 | 14 | 
| 1998 | 10 | 3 | 13 | 
| 1999 | 7 | 4 | 11 | 
| 2000 | 8 | 10 | 18 | 
| 2001 | 9 | 7 | 16 | 
| 2002 | 9 | 6 | 15 | 
| 2003 | 29 | 12 | 41 | 
| 2004 | 19 | 13 | 32 | 
| 2005 | 19 | 9 | 28 | 
| 2006 | 4 | 1 | 5 | 
| 2007 | 2 | 1 | 3 | 
| 2008 | 5 | 0 | 5 | 
| 2009 | 5 | 3 | 8 | 
| 2010 | 0 | 3 | 3 | 
| 2011 | 1 | 1 | 2 | 
| 2012 | 7 | 1 | 8 | 
| 2013 | 5 | 3 | 8 | 
| 2014 | 4 | 5 | 9 | 
| 2015 | 0 | 2 | 2 | 
| 2016 | 2 | 0 | 2 | 
| 2017 | 2 | 0 | 2 | 
| 2018 | 3 | 0 | 3 | 
| 2019 | 2 | 0 | 2 | 
| 2020 | 1 | 0 | 1 | 
| 2021 | 2 | 1 | 3 | 
| 2022 | 0 | 3 | 3 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
						
					
								- 
								
Sfrp4 expression in thyroxine treated calvarial cells. Life Sci. 2022 Dec 15; 311(Pt A):121158.
															
								 
							
								- 
								
Long non-coding RNA LINC00926 regulates WNT10B signaling pathway thereby altering inflammatory gene expression in PTSD. Transl Psychiatry. 2022 05 12; 12(1):200.
															
								 
							
								- 
								
Cigarette smoking is a secondary cause of folliculin loss. Thorax. 2023 Apr; 78(4):402-408.
															
								 
							
								- 
								
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
															
								 
							
								- 
								
Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766.
															
								 
							
								- 
								
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
															
								 
							
								- 
								
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
															
								 
							
								- 
								
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
															
								 
							
								- 
								
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol. 2020 01; 139(1):193-209.
															
								 
							
								- 
								
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chem Biol. 2018 09 20; 25(9):1107-1116.e4.